249 related articles for article (PubMed ID: 10325788)
61. Blood immunoreactive trypsinogen concentrations are genetically determined in healthy and cystic fibrosis newborns.
Lecoq I; Brouard J; Laroche D; Férec C; Travert G
Acta Paediatr; 1999 Mar; 88(3):338-41. PubMed ID: 10229049
[TBL] [Abstract][Full Text] [Related]
62. CFTR mutations and IVS8-5T variant in newborns with hypertrypsinaemia and normal sweat test.
Castellani C; Bonizzato A; Mastella G
J Med Genet; 1997 Apr; 34(4):297-301. PubMed ID: 9138152
[TBL] [Abstract][Full Text] [Related]
63. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols.
Gregg RG; Wilfond BS; Farrell PM; Laxova A; Hassemer D; Mischler EH
Am J Hum Genet; 1993 Mar; 52(3):616-26. PubMed ID: 7680526
[TBL] [Abstract][Full Text] [Related]
64. Evaluation of the Quantase neonatal immunoreactive trypsinogen (IRT) screening assay for cystic fibrosis.
Ball CL; Montgomery MD; Bridge PJ; Lyon ME
Clin Chem Lab Med; 2005; 43(5):570-2. PubMed ID: 15899682
[No Abstract] [Full Text] [Related]
65. Initial regional evaluation of the Cystic Fibrosis Newborn Screening Program: data from the Mediterranean coast of Turkey.
Başaran AE; Başaran A; Kocacik DF; Alper Ö; Acican D; Bingöl A
Turk J Med Sci; 2019 Dec; 49(6):1655-1661. PubMed ID: 31655510
[TBL] [Abstract][Full Text] [Related]
66. [Management of infants whose diagnosis is inconclusive at neonatal screening for cystic fibrosis].
Sermet-Gaudelus I; Brouard J; Audrézet MP; Couderc Kohen L; Weiss L; Wizla N; Vrielynck S; LLerena K; Le Bourgeois M; Deneuville E; Remus N; Nguyen-Khoa T; Raynal C; Roussey M; Girodon E
Arch Pediatr; 2017 Apr; 24(4):401-414. PubMed ID: 28258861
[TBL] [Abstract][Full Text] [Related]
67. Impact of IVS8-(TG)m(T)n on IRT and sweat chloride levels in newborns identified by California CF newborn screening.
Keiles S; Koepke R; Parad R; Kharrazi M;
J Cyst Fibros; 2012 May; 11(3):257-60. PubMed ID: 22209734
[TBL] [Abstract][Full Text] [Related]
68. Diagnosis of cystic fibrosis after newborn screening: the Australasian experience--twenty years and five million babies later: a consensus statement from the Australasian Paediatric Respiratory Group.
Massie J; Clements B;
Pediatr Pulmonol; 2005 May; 39(5):440-6. PubMed ID: 15704202
[TBL] [Abstract][Full Text] [Related]
69. Three common CFTR mutations should be included in a neonatal screening programme for cystic fibrosis in Sweden.
Schaedel C; Hjelte L; de Monestrol I; Johannesson M; Kollberg H; Kornfält R; Holmberg L
Clin Genet; 1999 Oct; 56(4):318-22. PubMed ID: 10636451
[TBL] [Abstract][Full Text] [Related]
70. [Newborn Screening on Cystic Fibrosis in Germany: Comparison of the new Screening Protocol with an Alternative Protocol].
Sommerburg O; Stahl M; Hammermann J; Okun JG; Kulozik A; Hoffmann G; Mall M
Klin Padiatr; 2017 Mar; 229(2):59-66. PubMed ID: 28444650
[No Abstract] [Full Text] [Related]
71. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels.
Rock MJ; Mischler EH; Farrell PM; Wei LJ; Bruns WT; Hassemer DJ; Laessig RH
Pediatrics; 1990 Jun; 85(6):1001-7. PubMed ID: 2187173
[TBL] [Abstract][Full Text] [Related]
72. Why cystic fibrosis newborn screening programs have failed to meet original expectations… thus far.
Farrell PM
Mol Genet Metab; 2023; 140(1-2):107679. PubMed ID: 37573205
[TBL] [Abstract][Full Text] [Related]
73. Genetic and clinical features of false-negative infants in a neonatal screening programme for cystic fibrosis.
Padoan R; Genoni S; Moretti E; Seia M; Giunta A; Corbetta C
Acta Paediatr; 2002; 91(1):82-7. PubMed ID: 11883825
[TBL] [Abstract][Full Text] [Related]
74. Neonatal screening for cystic fibrosis: result of a pilot study using both immunoreactive trypsinogen and cystic fibrosis gene mutation analyses.
Férec C; Verlingue C; Parent P; Morin JF; Codet JP; Rault G; Dagorne M; Lemoigne A; Journel H; Roussey M
Hum Genet; 1995 Nov; 96(5):542-8. PubMed ID: 8530001
[TBL] [Abstract][Full Text] [Related]
75. Cystic fibrosis newborn screening: shifting the key question from "should we screen?" to "how should we screen?".
Farrell PM
Pediatrics; 2004 Jun; 113(6):1811-2. PubMed ID: 15173512
[No Abstract] [Full Text] [Related]
76. Improving newborn screening for cystic fibrosis using next-generation sequencing technology: a technical feasibility study.
Baker MW; Atkins AE; Cordovado SK; Hendrix M; Earley MC; Farrell PM
Genet Med; 2016 Mar; 18(3):231-8. PubMed ID: 25674778
[TBL] [Abstract][Full Text] [Related]
77. Newborn screening for CF in France: An exemplary national experience.
Audrézet MP; Munck A
Arch Pediatr; 2020 Feb; 27 Suppl 1():eS35-eS40. PubMed ID: 32172935
[TBL] [Abstract][Full Text] [Related]
78. Optimization of the French cystic fibrosis newborn screening programme by a centralized tracking process.
Munck A; Delmas D; Audrézet MP; Lemonnier L; Cheillan D; Roussey M
J Med Screen; 2018 Mar; 25(1):6-12. PubMed ID: 28454512
[TBL] [Abstract][Full Text] [Related]
79. CF versus CRMS: diagnostic challenges in cystic fibrosis.
Temme R; Roggenbuck J; McNamara J
Minn Med; 2012 Oct; 95(10):42-4. PubMed ID: 23193705
[TBL] [Abstract][Full Text] [Related]
80. Refining the continuum of CFTR-associated disorders in the era of newborn screening.
Levy H; Nugent M; Schneck K; Stachiw-Hietpas D; Laxova A; Lakser O; Rock M; Dahmer MK; Biller J; Nasr SZ; Baker M; McColley SA; Simpson P; Farrell PM
Clin Genet; 2016 May; 89(5):539-49. PubMed ID: 26671754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
